Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOQJZC)

• Drug Name: Bisindolylmaleimide-I Drug Info
• Synonyms: Bisindolylmaleimide i; bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; 6850; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1] , [2] , [3]

• Cross-matching ID:
  PubChem CID: 2396
  CAS Number: CAS 133052-90-1
  TTD Drug ID: DMOQJZC
  VARIDT Drug ID: DR00622

Molecule-Related Drug Atlas

Drug(s) Targeting LCK tyrosine protein kinase (LCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Chronic myelogenous leukaemia	2A20.0	Approved	[8]
VX-680	DM93YKJ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
JNJ-26483327	DMSQ3AZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
ISIS-CRP	DMQDUG4	Cardiovascular disease	BA00-BE2Z	Phase 1	[10]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[5]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[11]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[5]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[12]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[13]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Stress-activated protein kinase JNK1 (JNK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NKP-1339	DM5AWK1	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[15]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[15]
7-azaindole derivative 1	DMQL5B7	N. A.	N. A.	Patented	[15]
7-azaindole derivative 5	DMV3H98	N. A.	N. A.	Patented	[15]
PMID25991433-Compound-P6	DMNDVC9	N. A.	N. A.	Patented	[15]
PMID25991433-Compound-J3	DM17P3F	N. A.	N. A.	Patented	[15]
PMID25991433-Compound-P1	DMD8AX6	N. A.	N. A.	Patented	[15]
PMID25991433-Compound-O3	DMVOWS5	N. A.	N. A.	Patented	[15]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[15]

Drug(s) Targeting Protein kinase C gamma (PRKCG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[8]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[16]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[17]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[18]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[19]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[20]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[20]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[20]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[20]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[21]

Drug(s) Targeting PKC-delta messenger RNA (PRKCD mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[16]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[21]
PROSTRATIN	DM1HMJ5	Human immunodeficiency virus infection	1C62	Investigative	[22]
8-Octyl-benzolactam-V9	DM4Z15M	Discovery agent	N.A.	Investigative	[23]
Go 6983	DMKVTZN	Discovery agent	N.A.	Investigative	[24]
Diheptan-3-yl 5-(hydroxymethyl)isophthalate	DMBAY7P	Discovery agent	N.A.	Investigative	[25]
Dihexan-3-yl 5-(hydroxymethyl)isophthalate	DM8TBQ9	Discovery agent	N.A.	Investigative	[25]
ISIS 10310	DMT6H9S	Discovery agent	N.A.	Investigative	[26]
ISIS 17252	DMW40NK	Discovery agent	N.A.	Investigative	[27]
ISIS 10303	DM205TE	Discovery agent	N.A.	Investigative	[26]

Drug(s) Targeting Cyclin-dependent kinase 1 (CDK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[28]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[28]
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[29]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[30]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[28]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[31]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[32]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[15]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[33]

Drug(s) Targeting Rho-associated protein kinase 1 (ROCK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Netarsudil	DM0LPI9	Open-angle glaucoma	9C61	Approved	[34]
SAR-407899	DMF95KD	Diabetic nephropathy	GB61.Z	Phase 2	[35]
H-1152	DM8XH3S	Pulmonary arterial hypertension	BB01.0	Phase 2	[36]
INS-117548	DMA46DO	Glaucoma/ocular hypertension	9C61	Phase 1	[37]
GSK269962A	DM5I2HL	Inflammation	1A00-CA43.1	Clinical trial	[38]
PMID28048944-Compound-19	DMPT3V9	N. A.	N. A.	Patented	[39]
PMID28048944-Compound-3	DM1BN74	N. A.	N. A.	Patented	[39]
PMID28048944-Compound-7	DMXZ368	N. A.	N. A.	Patented	[39]
PMID28048944-Compound-4	DMJAUWG	N. A.	N. A.	Patented	[39]
PMID28048944-Compound-5	DMAB987	N. A.	N. A.	Patented	[39]

Drug(s) Targeting Stress-activated protein kinase 2b (p38 beta)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[40]
SB 235699	DMNH8XU	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[40]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[5]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[11]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[5]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[5]
Ro31-8220	DMDJLF0	Discovery agent	N.A.	Investigative	[5]
STAUROSPORINONE	DMU2H4K	Discovery agent	N.A.	Investigative	[5]
KT-5720	DM9J50F	Discovery agent	N.A.	Investigative	[5]
L-779450	DM51B74	Discovery agent	N.A.	Investigative	[41]

Drug(s) Targeting Extracellular signal-regulated kinase 2 (ERK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BVD-523	DMNB4XK	Melanoma	2C30	Phase 2	[42]
HH2710	DM0C5MV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[43]
ASTX029	DMVZXIA	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[44]
VAN-10-4-eluting stent	DM3ZW6A	Artery stenosis	BD52	Phase 1	[45]
GDC-0994	DMFC2OY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[46]
JSI-1187	DMVJWBS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[47]
LY3214996	DMFDAY7	Solid tumour/cancer	2A00-2F9Z	Phase 1	[48]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[49]
COR-D	DMLXMCB	T-cell leukaemia	2A90	Preclinical	[50]
SB220025	DMSBUET	Arthritis	FA20	Terminated	[51]

Drug(s) Targeting Protein kinase C zeta (PRKCZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methyl 2-amino-4-phenylthiophene-3-carboxylate	DM9BYJ0	N. A.	N. A.	Patented	[52]
Y-9680	DMHAVYS	N. A.	N. A.	Patented	[52]
US8889696, 39	DMKXRJ4	N. A.	N. A.	Patented	[53]
US8889672, 252-036-001	DM8B1Q4	N. A.	N. A.	Patented	[52]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[17]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[18]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[19]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[21]
[2,2':5',2'']Terthiophen-4-yl-methanol	DMRQC1F	Discovery agent	N.A.	Investigative	[54]
4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	DM8IYG1	Discovery agent	N.A.	Investigative	[55]

Drug(s) Targeting Checkpoint kinase-1 (CHK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY2603618	DMCXRZF	Pancreatic cancer	2C10	Phase 2	[56]
UCN-01	DMUNJZB	Non-small-cell lung cancer	2C25.Y	Phase 2	[57]
SCH-900776	DM67EMK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[58]
LY2606368	DM4XMF7	Ovarian cancer	2C73	Phase 2	[48]
LY2880070	DMADEHZ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[59]
RG7741	DMK6P9J	Lymphoma	2A80-2A86	Phase 1	[60]
GDC-0425	DMDZ26X	Lymphoma	2A80-2A86	Phase 1	[61]
AZD7762	DM1FW0C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[62]
MK-8776	DMAS1RB	Hodgkin lymphoma	2B30	Phase 1	[63]
Diamidothiazole derivative 1	DM02V5Q	N. A.	N. A.	Patented	[32]

Drug(s) Targeting Serine/threonine-protein kinase Sgk1 (SGK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[5]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[11]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[5]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[5]
CGP-57380	DMFPOUC	Discovery agent	N.A.	Investigative	[10]
GSK-650394	DMNRP2L	Prostate cancer	2C82.0	Investigative	[64]

Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ozagrel	DMIGKA1	Xerophthalmia	5B55.Y	Phase 4	[65]
Losmapimod	DMIL37Z	Acute coronary syndrome	BA41	Phase 3	[65]
VX-702	DMKJDR6	Coronary artery disease	BA80	Phase 2a	[66]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[40]
Dilmapimod	DMBYJ92	Acute lung injury	NB32.3	Phase 2	[65]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[15]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[15]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[15]
PMID25991433-Compound-L3	DM3LWUR	N. A.	N. A.	Patented	[15]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[15]

Drug(s) Targeting RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[48]
AZD5363	DM9SKW8	Triple negative breast cancer	2C60-2C65	Phase 3	[48]
GDC-0068	DMWBZJD	Breast cancer	2C60-2C65	Phase 3	[48]
CI-1033	DMSI8N3	Lymphoma	2A80-2A86	Phase 2	[8]
CMX-2043	DMPSCVY	Cardiac disease	BA00-BE2Z	Phase 2	[67]
ARQ 092	DM5WK0J	Proteus syndrome	LD2C	Phase 2	[68]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[69]
RX-0201	DMTBAV3	Pancreatic cancer	2C10	Phase 2	[70]
Trametinib + 2141795	DMYP7TO	Solid tumour/cancer	2A00-2F9Z	Phase 2	[69]
PTX-200	DM0ZIT2	Breast cancer	2C60-2C65	Phase 2	[48]

Drug(s) Targeting Glycogen synthase kinase-3 beta (GSK-3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMO-02	DMJRU3A	Myotonic dystrophy	8C71.0	Phase 2/3	[71]
LY2090314	DMTBFE4	Acute myeloid leukaemia	2A60	Phase 2	[72]
Lithium	DMZ3OU6	Fragile X syndrome	LD55	Phase 2	[73]
Tideglusib	DME4LA1	Osteosarcoma	2B51	Phase 2	[74]
9-ING-41	DM57TY3	Myelofibrosis	2A20.2	Phase 2	[75]
Neu-120	DMXKOUC	Parkinson disease	8A00.0	Phase 1/2	[76]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[77]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[49]
TDZD-8	DMG6Q45	Malignant glioma	2A00.0	Patented	[78]
AR-A014418	DMUPN01	Ovarian cancer	2C73	Patented	[79]

Drug(s) Targeting Bacterial Lethal factor (Bact lef)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IQ-DAA	DMHP71R	Bacillus anthracis infection	1G40	Phase 1	[80]
GM6001	DM7V9CT	Corneal ulcer	9A76	Discontinued in Phase 2	[51]
MMI270	DM38N2K	Discovery agent	N.A.	Investigative	[81]
NSC-622445	DME35CB	Discovery agent	N.A.	Investigative	[82]
N-(Sulfanylacetyl)Tyrosylprolylmethioninamide	DMWJDYZ	Discovery agent	N.A.	Investigative	[51]
N-(3,4-dihydroxybenzyl)oleamide	DM67XSW	Discovery agent	N.A.	Investigative	[83]
N,N'-Bis(4-Amino-2-Methylquinolin-6-Yl)Urea	DMT4USP	Discovery agent	N.A.	Investigative	[51]
N-hydroxy-4-(oleamidomethyl)benzamide	DMUSHZK	Discovery agent	N.A.	Investigative	[83]
N-(3,4,5-trihydroxyphenethyl)oleamide	DMQ5USA	Discovery agent	N.A.	Investigative	[84]
N-oleoyl-dopamine	DM1AVCZ	Discovery agent	N.A.	Investigative	[84]

Drug(s) Targeting MAP kinase p38 (MAPK12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SM-101	DMFX9O6	Idiopathic thrombocytopenic purpura	3B64.10	Approved (orphan drug)	[85]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[86]
ARRY-797	DMJ48AB	Dilated cardiomyopathy	BC43.0	Phase 2	[87]
KC706	DMBX6C7	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[88]
SB 235699	DMNH8XU	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[89]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[5]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[11]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[5]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[12]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Protein kinase C (PRKC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Synthetic hypericin	DMXU4ON	Virus infection	1A24-1D9Z	Phase 3	[90]
APH-0812	DM756GE	Human immunodeficiency virus-1 infection	1C62	Phase 2	[91]
CYCLOPLATAM	DMXR8WN	Solid tumour/cancer	2A00-2F9Z	Phase 2	[92]
AEB07	DMJVN89	Transplant rejection	NE84	Phase 2	[93]
HO/03/03	DMA6HQJ	Diabetic foot ulcer	BD54	Phase 2	[94]
LXS196	DM65MEL	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[48]
Safingol	DMBGUDR	Psoriasis vulgaris	EA90	Phase 1	[95]
GCC-1290K	DMJ7WRI	Parkinson disease	8A00.0	Phase 1	[96]
AEB701	DM8I4G0	Melanoma	2C30	Phase 1	[97]
Tecadenoson	DM9T6MS	Atrial fibrillation	BC81.3	Discontinued in Phase 3	[98]

Drug(s) Targeting PKC-epsilon messenger RNA (PRKCE mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[16]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[99]
PROSTRATIN	DM1HMJ5	Human immunodeficiency virus infection	1C62	Investigative	[22]
8-Octyl-benzolactam-V9	DM4Z15M	Discovery agent	N.A.	Investigative	[23]
Chelerythrine	DMCP1G9	Discovery agent	N.A.	Investigative	[100]
ISIS 7942	DMN0A1R	Discovery agent	N.A.	Investigative	[26]
ISIS 7948	DMYZE8R	Discovery agent	N.A.	Investigative	[26]

Drug(s) Targeting G2/mitotic-specific cyclin B1 (CCNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[33]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[3]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[20]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[20]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[20]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[20]
AZAKENPAULLONE	DM61H07	Discovery agent	N.A.	Investigative	[77]
Thieno analogue of kenpaullone	DMIOTHG	Discovery agent	N.A.	Investigative	[77]
3,4-bis(indol-3-yl)maleimide derivative	DMEQ1HC	Discovery agent	N.A.	Investigative	[3]
4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine	DMDW3SX	Discovery agent	N.A.	Investigative	[101]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Lethal factor (Bact lef)	TTIQSC1	LEF_BACAN	Inhibitor	[4]
Checkpoint kinase-1 (CHK1)	TTTU902	CHK1_HUMAN	Inhibitor	[5]
Cyclin-dependent kinase 1 (CDK1)	TTH6V3D	CDK1_HUMAN	Inhibitor	[3]
Extracellular signal-regulated kinase 2 (ERK2)	TT4TQBX	MK01_HUMAN	Inhibitor	[5]
G2/mitotic-specific cyclin B1 (CCNB1)	TT9P6OW	CCNB1_HUMAN	Inhibitor	[3]
Glycogen synthase kinase-3 beta (GSK-3B)	TTRSMW9	GSK3B_HUMAN	Inhibitor	[5]
LCK tyrosine protein kinase (LCK)	TT860QF	LCK_HUMAN	Inhibitor	[5]
MAP kinase p38 (MAPK12)	TTYT93M	MK12_HUMAN	Inhibitor	[5]
PKC-delta messenger RNA (PRKCD mRNA)	TT7A1BO	KPCD_HUMAN	Inhibitor	[6]
PKC-epsilon messenger RNA (PRKCE mRNA)	TT57MT2	KPCE_HUMAN	Inhibitor	[6]
Protein kinase C (PRKC)	TTYVX59	NOUNIPROTAC	Inhibitor	[2]
Protein kinase C gamma (PRKCG)	TTRFOXJ	KPCG_HUMAN	Inhibitor	[6]
Protein kinase C zeta (PRKCZ)	TTUWGRA	KPCZ_HUMAN	Inhibitor	[7]
RAC-alpha serine/threonine-protein kinase (AKT1)	TTWTSCV	AKT1_HUMAN	Inhibitor	[5]
Rho-associated protein kinase 1 (ROCK1)	TTZN7RP	ROCK1_HUMAN	Inhibitor	[5]
Serine/threonine-protein kinase Sgk1 (SGK1)	TTTV8EJ	SGK1_HUMAN	Inhibitor	[5]
Stress-activated protein kinase 2a (p38 alpha)	TTQBR95	MK14_HUMAN	Inhibitor	[5]
Stress-activated protein kinase 2b (p38 beta)	TT73U6C	MK11_HUMAN	Inhibitor	[5]
Stress-activated protein kinase JNK1 (JNK1)	TT0K6EO	MK08_HUMAN	Inhibitor	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5193).
• [2] Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8.
• [3] Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
• [4] Amiodarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob Agents Chemother. 2007 Jul;51(7):2403-11.
• [5] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [6] Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63.
• [7] Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15.
• [8] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [9] National Cancer Institute Drug Dictionary (drug id 596693).
• [10] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
• [11] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [12] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [13] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
• [15] c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
• [16] Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
• [17] Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
• [18] Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
• [19] Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
• [20] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [21] (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
• [22] A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
• [23] Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8.
• [24] Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80.
• [25] Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem. 2009 Jul 9;52(13):3969-81.
• [26] US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
• [27] US patent application no. 6,235,723, Antisense oligonucleotide modulation of human protein kinase C-.delta. expression.
• [28] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [29] P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
• [30] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
• [31] A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
• [32] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [33] Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
• [34] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [35] The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9.
• [36] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [37] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [38] Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
• [39] Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
• [40] Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
• [41] The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
• [42] DOI: 10.1158/1538-7445.AM2015-4693
• [43] Clinical pipeline report, company report or official report of HaiHe Biopharma.
• [44] Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
• [45] WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
• [46] ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
• [47] National Cancer Institute Drug Dictionary (drug name JSI1187).
• [48] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [49] Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
• [50] Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
• [51] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [52] Compounds, formulations, and methods of protein kinase C inhibition. US8889672.
• [53] Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof. US8889696.
• [54] Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
• [55] Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
• [56] Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
• [57] Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
• [58] Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
• [59] A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
• [60] National Cancer Institute Drug Dictionary (drug id 730054).
• [61] Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
• [62] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [63] Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095.
• [64] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8040).
• [65] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [66] Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
• [67] Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
• [68] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [69] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
• [70] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [71] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [72] Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
• [73] The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
• [74] Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
• [75] 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
• [76] Company report (Neurim Pharmaceuticals)
• [77] 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
• [78] Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
• [79] Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
• [80] Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Future Microbiol.2009 Feb;4(1):35-43.
• [81] The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8.
• [82] Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. J Med Chem. 2006 Aug 24;49(17):5232-44.
• [83] Inhibitors of anthrax lethal factor based upon N-oleoyldopamine. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2467-70.
• [84] Inhibitors of anthrax lethal factor. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4575-8.
• [85] Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
• [86] P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22.
• [87] Array BioPharmas ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs
• [88] KC706, an Oral p38 MAP Kinase Inhibitor, Increases HDL-C. Circulation. 2007;116:II_126.
• [89] Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem. 2003 Dec 18;46(26):5651-62.
• [90] Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006 May-Jun;82(3):720-8.
• [91] Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
• [92] Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73.
• [93] What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81.
• [94] WO patent application no. 2014,0853,81, Pharmaceutical combinations.
• [95] The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol. 2009 Dec;35(6):1463-71.
• [96] Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
• [97] Changes in Serum Cytokine Profile after AEB071 (Sotrastaurin) or Tacrolimus versus Their Combinations in Rat Heterotopic Cardiac Allografts. J Korean Soc Transplant. 2012 Dec;26(4):248-253.
• [98] Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr Cancer. 2001;40(1):55-63.
• [99] Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4.
• [100] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [101] Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86.